Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Gilad&Gilad, The Health Science Company, Re-Gambles on Las Vegas*


News provided by

Gilad&Gilad LLC

Jun 06, 2023, 09:45 ET

Share this article

Share toX

Share this article

Share toX

G&G Logo - Fight For Nerve Health
G&G Logo - Fight For Nerve Health

The health science company is expecting to scale up development and marketing efforts of its Agmaceuticals™ line of dietary supplement products for nerve health.

LAS VEGAS, June 6, 2023 /PRNewswire-PRWeb/ -- Gilad&Gilad, a health science company with a core competency in neuroscience and a focus on the development and marketing of innovative nerve health solutions, announced today that it is presently relocating its headquarters to Las Vegas, Nevada. This move is in fact the return of the company to its home base after a two-year stint in Texas spent on clinical trials. The return to Vegas signifies the re-direction of efforts towards development and marketing of its agmatine-based nutraceutical supplements.

"Moving back to Vegas will allow the company to allocate more resources to the marketing efforts of our signature supplements products, AgmaSet® and AgmaVet®, targeting nerve health," said Gad M. Gilad, PhD, co-founder, and CEO of Gilad&Gilad. "And at the same time, it will enable us to continue our investments in developing new novel products aimed at promoting healthy functions of bodily systems other than the nervous system," he added.

“Moving back to Vegas will allow the company to allocate more resources to the marketing efforts of our signature supplements products, AgmaSet® and AgmaVet®, targeting nerve health.”

Post this

Throughout these conversions from Nevada to Texas and back, the company continues to maintain its contract manufacturing operations in California. "We prefer to continue working with our long-time manufacturer with whom we have established good rapport and trust. Another advantage of our relocation to Vegas is the proximity to South California where our CMO is located. We can, therefore, assure our customers that the highest quality they expect of our products will be absolutely maintained." indicated Gilad.

Source: Gilad&Gilad LLC, a health science company with core competency in Neuroscience, develops, manufactures, and markets the Agmaceuticals™ line of products, first-of-their-kind nutraceuticals, containing G-Agmatine® (the best brand of agmatine).

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

-------------------------------------------------------------------------
Gilad&Gilad LLC is a health science company with core competency in Neuroscience. The company has developed the exclusive Agmaceuticals™ line of products based on the breakthrough discovery of the neuroprotective properties agmatine. AgmaSet® (a dietary supplement) and AgmaVet® (for animals) are first-of-their-kind nutraceutical products containing G-Agmatine® (the best brand of agmatine), superior to existing modalities for nerve health and resilient nerve functions. – For further information, visit: https://ForNerveHealth.com. – The Company seeks investments and distributors and is open to acquisition or licensing inquiries.

About the Founders of Gilad&Gilad
Dr. Gad M. Gilad and Mrs. Varda H. Gilad began their careers in the1970s as scientists at Cornell University and The Rockefeller University, respectively. Their common scientific interests led them to join forces in 1979 and begin a long-lasting legend of a wife and husband team effort aimed at unraveling molecular mechanisms which underlie the ability of the nervous system to cope with trauma and stress. They worked together at several academic centers including the National Institutes of Health, the Weizmann Institute of Science and Harvard University. They received numerous research grants and several awards and together published over 100 scientific papers and several patents. In 1994 they discovered the neuroprotective properties of G-Agmatine® (their proprietary brand of agmatine) and patented its use for enhancing the nervous system ability to cope with trauma and stress. In 2000 following years of extensive scientific research on agmatine's molecular mechanisms of action, they founded the Company to pursue the commercial development of G-agmatine® as a nutraceutical. In 2004, they conducted the first ever human clinical trials with G-agmatine® and demonstrated its safety and effectiveness for healthy nerve functions. In 2009, the Company set up headquarters in the United States, and established a commercial production and marketing base for the exclusive Agmaceuticals™ product line. AgmaSet®, for humans, and AgmaVet®, for animals, are novel, first-of-their-kind nutraceutical supplements, superior to any other products presently on the market for healthier nerve functions.

Media Contact

Gad M. Gilad, Ph.D. Research, Gilad&Gilad, Gilad&Gilad LLC, 1 323-599-0774, [email protected]

LinkedIn

SOURCE Gilad&Gilad LLC

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.